KAT2A: Unlocking The Potential of Key Enzyme in Cellular Processes

Target Name: KAT2A

NCBI ID: G2648

KAT2A

KAT2A: Unlocking The Potential of Key Enzyme in Cellular Processes

Histone succinyltransferase KAT2A (KAT2A) is a gene that has been well-studied for its role in various cellular processes. KAT2A is a key enzyme in the succinyltransferase complex, which is responsible for the transfer of succinyl groups from histones to other proteins. This enzyme has been shown to play a crucial role in the regulation of cell proliferation, differentiation, and metabolism.

KAT2A is a member of the KAT family of enzymes, which includes the Ku70 and KAT67 enzymes. The KAT family is known for its role in the regulation of DNA replication and repair. The KAT2A enzyme has been shown to be involved in the regulation of DNA replication, specifically in the repair of DNA damage.

KAT2A has also been shown to be involved in the regulation of cell signaling pathways. For example, KAT2A has been shown to be involved in the regulation of theNotch signaling pathway. This pathway is known for its role in the regulation of cell proliferation and survival, and has been implicated in various diseases, including cancer.

In addition to its role in cellular signaling pathways, KAT2A has also been shown to be involved in the regulation of cell adhesion. This is important for the proper functioning of various tissues and organs, including tissues involved in the development and maintenance of tissues, such as the skin and hair.

KAT2A has also been shown to play a role in the regulation of cellular transport. This is important for the proper functioning of various cellular processes, including the movement of proteins and other molecules within cells.

Despite its importance in numerous cellular processes, KAT2A is not yet widely understood or targeted. There is a need for further research to fully understand the role of KAT2A in cellular processes, as well as its potential as a drug target or biomarker.

One potential way to target KAT2A is through the use of small molecules or antibodies that specifically interact with the enzyme. This could be done to either inhibit or enhance the activity of KAT2A, depending on the desired effect. For example, small molecules that inhibit the activity of KAT2A could be used to treat conditions characterized by high levels of cell proliferation, such as cancer. On the other hand, antibodies that specifically interact with KAT2A could be used to detect or measure the activity of the enzyme in various cellular processes.

Another potential way to target KAT2A is through the use of drugs that specifically target the succinyltransferase complex. This could involve the use of drugs that inhibit the activity of succinyltransferase enzymes, including KAT2A. These drugs could be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD).

In conclusion, KAT2A is an important enzyme involved in various cellular processes. Despite its importance, the field of its research is still in its infancy. Further research is needed to fully understand the role of KAT2A in cellular processes, as well as its potential as a drug target or biomarker. The development of new treatments and therapies based on the understanding of KAT2A could have a significant impact on the treatment of various diseases.

Protein Name: Lysine Acetyltransferase 2A

Functions: Protein lysine acyltransferase that can act as a acetyltransferase, glutaryltransferase, succinyltransferase or malonyltransferase, depending on the context (PubMed:29211711, PubMed:35995428). Acts as a histone lysine succinyltransferase: catalyzes succinylation of histone H3 on 'Lys-79' (H3K79succ), with a maximum frequency around the transcription start sites of genes (PubMed:29211711). Succinylation of histones gives a specific tag for epigenetic transcription activation (PubMed:29211711). Association with the 2-oxoglutarate dehydrogenase complex, which provides succinyl-CoA, is required for histone succinylation (PubMed:29211711). In different complexes, functions either as an acetyltransferase (HAT) or as a succinyltransferase: in the SAGA and ATAC complexes, acts as a histone acetyltransferase (PubMed:17301242, PubMed:19103755, PubMed:29211711). Has significant histone acetyltransferase activity with core histones, but not with nucleosome core particles (PubMed:17301242, PubMed:19103755). Acetylation of histones gives a specific tag for epigenetic transcription activation (PubMed:17301242, PubMed:19103755, PubMed:29211711). Recruited by the XPC complex at promoters, where it specifically mediates acetylation of histone variant H2A.Z.1/H2A.Z, thereby promoting expression of target genes (PubMed:29973595, PubMed:31527837). Involved in long-term memory consolidation and synaptic plasticity: acts by promoting expression of a hippocampal gene expression network linked to neuroactive receptor signaling (By similarity). Acts as a positive regulator of T-cell activation: upon TCR stimulation, recruited to the IL2 promoter following interaction with NFATC2 and catalyzes acetylation of histone H3 at 'Lys-9' (H3K9ac), leading to promote IL2 expression (By similarity). Required for growth and differentiation of craniofacial cartilage and bone by regulating acetylation of histone H3 at 'Lys-9' (H3K9ac) (By similarity). Regulates embryonic stem cell (ESC) pluripotency and differentiation (By similarity). Also acetylates non-histone proteins, such as CEBPB, PPARGC1A, PLK4 and TBX5 (PubMed:17301242, PubMed:16753578, PubMed:27796307, PubMed:29174768). Involved in heart and limb development by mediating acetylation of TBX5, acetylation regulating nucleocytoplasmic shuttling of TBX5 (PubMed:29174768). Acts as a negative regulator of centrosome amplification by mediating acetylation of PLK4 (PubMed:27796307). Acts as a negative regulator of gluconeogenesis by mediating acetylation and subsequent inactivation of PPARGC1A (PubMed:16753578, PubMed:23142079). Also acts as a histone glutaryltransferase: catalyzes glutarylation of histone H4 on 'Lys-91' (H4K91glu), a mark that destabilizes nucleosomes by promoting dissociation of the H2A-H2B dimers from nucleosomes (PubMed:31542297)

The "KAT2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KAT2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets